Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BRIDGEWATER, N.J., April 27, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at the Deutsche Bank 42nd Annual Health Care Conference in Boston, MA on Thursday, May 4, 2017 at 10:40 a.m. ET.
Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare disorders, including pulmonary arterial hypertension (PAH). For more information, visit www.insmed.com.
Investor Contact: Laura Perry or Heather Savelle Argot Partners 212-600-1902 [email protected] [email protected]
